Supreme Court Pauses Ruling Restricting Abortion Pill by Mail

On May 4, 2026, the U.S. Supreme Court issued a temporary pause on a lower court's decision that mandated in-person visits to healthcare providers for obtaining the abortion pill mifepristone. This administrative stay, granted by Justice Samuel Alito, allows the continued distribution of mifepristone via mail while the Court considers the case further.

The pause is in response to appeals from Danco Laboratories LLC and GenBioPro Inc., manufacturers of mifepristone and its generic counterpart, respectively. These companies argued that the appellate court's ruling created confusion and restricted access to the medication, even in states where abortion remains legal.

Mifepristone is a key component in medication abortions and has been at the center of ongoing legal debates concerning reproductive rights and access to abortion services. The Supreme Court's intervention highlights the ongoing legal complexities surrounding abortion access in the United States.

The administrative stay is set to remain in effect until May 11, providing the Court additional time to deliberate on the matter. The outcome of this case could have significant implications for the FDA's authority over medication distribution and the broader landscape of reproductive healthcare.

For more detailed information, refer to the original article on Bloomberg Law: Supreme Court Pauses Ruling That Restricts Abortion Pill by Mail.